|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Krawczyk N, Meier-Stiegen F, Banys M,
Neubauer H, Ruckhaeberle E and Fehm T: Expression of stem cell and
epithelial-mesenchymal transition markers in circulating tumor
cells of breast cancer patients. BioMed Res Int. 2014:4157212014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen C, Zimmermann M, Tinhofer I, Kaufmann
AM and Albers AE: Epithelial-to-mesenchymal transition and cancer
stem(−like) cells in head and neck squamous cell carcinoma. Cancer
Lett. 338:47–56. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Loboda A, Nebozhyn MV, Watters JW, Buser
CA, Shaw PM, Huang PS, Veer Vant L, Tollenaar RA, Jackson DB,
Agrawal D, et al: EMT is the dominant program in human colon
cancer. BMC Med Genomics. 4:92011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bates RC, Goldsmith JD, Bachelder RE,
Brown C, Shibuya M, Oettgen P and Mercurio AM: Flt-1-dependent
survival characterizes the epithelial-mesenchymal transition of
colonic organoids. Curr Biol. 13:1721–1727. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iwai S, Yonekawa A, Harada C, Hamada M,
Katagiri W, Nakazawa M and Yura Y: Involvement of the Wnt-β-catenin
pathway in invasion and migration of oral squamous carcinoma cells.
Int J Oncol. 37:1095–1103. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu TH, Yao Y, Yu S, Han LL, Wang WJ, Guo
H, Tian T, Ruan ZP, Kang XM, Wang J, et al: SDF-1/CXCR4 promotes
epithelial-mesenchymal transition and progression of colorectal
cancer by activation of the Wnt/β-catenin signaling pathway. Cancer
Lett. 354:417–426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He W, He S, Wang Z, Shen H, Fang W, Zhang
Y, Qian W, Lin M, Yuan J, Wang J, et al: Astrocyte elevated gene-1
(AEG-1) induces epithelial-mesenchymal transition in lung cancer
through activating Wnt/β-catenin signaling. BMC Cancer. 15:1072015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsuchiya R, Yamamoto G, Nagoshi Y, Aida T,
Irie T and Tachikawa T: Expression of adenomatous polyposis coli
(APC) in tumorigenesis of human oral squamous cell carcinoma. Oral
Oncol. 40:932–940. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sabbah M, Emami S, Redeuilh G, Julien S,
Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O and Gespach C:
Molecular signature and therapeutic perspective of the
epithelial-to-mesenchymal transitions in epithelial cancers. Drug
Resist Updat. 11:123–151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gilles C, Polette M, Mestdagt M,
Nawrocki-Raby B, Ruggeri P, Birembaut P and Foidart JM:
Transactivation of vimentin by beta-catenin in human breast cancer
cells. Cancer Res. 63:2658–2664. 2003.PubMed/NCBI
|
|
17
|
Guo M, Ehrlicher AJ, Mahammad S, Fabich H,
Jensen MH, Moore JR, Fredberg JJ, Goldman RD and Weitz DA: The role
of vimentin intermediate filaments in cortical and cytoplasmic
mechanics. Biophys J. 105:1562–1568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pan Y and Li X, Duan J, Yuan L, Fan S, Fan
J, Xiaokaiti Y, Yang H, Wang Y and Li X: Enoxaparin sensitizes
human non-small-cell lung carcinomas to gefitinib by inhibiting
DOCK1 expression, vimentin phosphorylation, and Akt activation. Mol
Pharmacol. 87:378–390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Satelli A, Brownlee Z, Mitra A, Meng QH
and Li S: Circulating tumor cell enumeration with a combination of
epithelial cell adhesion molecule- and cell-surface vimentin-based
methods for monitoring breast cancer therapeutic response. Clin
Chem. 61:259–266. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Calangiu CM, Simionescu CE, Stepan AE,
Cernea D, Zăvoi RE and Mărgăritescu C: The expression of CK19,
vimentin and E-cadherin in differentiated thyroid carcinomas. Rom J
Morphol Embryol. 55:919–925. 2014.PubMed/NCBI
|
|
21
|
Shirahata A, Sakata M, Sakuraba K, Goto T,
Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, et
al: Vimentin methylation as a marker for advanced colorectal
carcinoma. Anticancer Res. 29:279–281. 2009.PubMed/NCBI
|
|
22
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Natalwala A, Spychal R and Tselepis C:
Epithelial-mesenchymal transition mediated tumourigenesis in the
gastrointestinal tract. World J Gastroenterol. 14:3792–3797. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marsit CJ, Posner MR, McClean MD and
Kelsey KT: Hypermethylation of E-cadherin is an independent
predictor of improved survival in head and neck squamous cell
carcinoma. Cancer. 113:1566–1571. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pannone G, Santoro A, Feola A, Bufo P,
Papagerakis P, Lo Muzio L, Staibano S, Ionna F, Longo F, Franco R,
et al: The role of E-cadherin down-regulation in oral cancer: CDH1
gene expression and epigenetic blockage. Curr Cancer Drug Targets.
14:115–127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cekanova M, Fernando RI, Siriwardhana N,
Sukhthankar M, De la Parra C, Woraratphoka J, Malone C, Ström A,
Baek SJ, Wade PA, et al: BCL-2 family protein, BAD is
down-regulated in breast cancer and inhibits cell invasion. Exp
Cell Res. 331:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cui T, Srivastava AK, Han C, Yang L, Zhao
R, Zou N, Qu M, Duan W, Zhang X and Wang QE: XPC inhibits NSCLC
cell proliferation and migration by enhancing E-Cadherin
expression. Oncotarget. 6:10060–10072. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hazan RB, Phillips GR, Qiao RF, Norton L
and Aaronson SA: Exogenous expression of N-cadherin in breast
cancer cells induces cell migration, invasion, and metastasis. J
Cell Biol. 148:779–790. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim JB, Islam S, Kim YJ, Prudoff RS, Sass
KM, Wheelock MJ and Johnson KR: N-Cadherin extracellular repeat 4
mediates epithelial to mesenchymal transition and increased
motility. J Cell Biol. 151:1193–1206. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qi J, Chen N, Wang J and Siu CH:
Transendothelial migration of melanoma cells involves
N-cadherin-mediated adhesion and activation of the beta-catenin
signaling pathway. Mol Biol Cell. 16:4386–4397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vergara D, Simeone P, Latorre D, Cascione
F, Leporatti S, Trerotola M, Giudetti AM, Capobianco L, Lunetti P,
Rizzello A, et al: Proteomics analysis of E-cadherin knockdown in
epithelial breast cancer cells. J Biotechnol. 202:3–11. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Florian S, Sonneck K, Czerny M,
Hennersdorf F, Hauswirth AW, Bühring HJ and Valent P: Detection of
novel leukocyte differentiation antigens on basophils and mast
cells by HLDA8 antibodies. Allergy. 61:1054–1062. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tan EJ, Kahata K, Idås O, Thuault S,
Heldin CH and Moustakas A: The high mobility group A2 protein
epigenetically silences the Cdh1 gene during
epithelial-to-mesenchymal transition. Nucleic Acids Res.
43:162–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Furukawa T, Adachi Y, Fujisawa J, Kambe T,
Yamaguchi-Iwai Y, Sasaki R, Kuwahara J, Ikehara S, Tokunaga R and
Taketani S: Involvement of PLAGL2 in activation of iron deficient-
and hypoxia-induced gene expression in mouse cell lines. Oncogene.
20:4718–4727. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Landrette SF, Kuo YH, Hensen K, van
Barjesteh Waalwijk van Doorn-Khosrovani S, Perrat PN, Van de Ven
WJ, Delwel R and Castilla LH: Plag1 and Plagl2 are oncogenes that
induce acute myeloid leukemia in cooperation with Cbfb-MYH11.
Blood. 105:2900–2907. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang YS, Yang MC and Weissler JC:
Pleiomorphic adenoma gene-like 2 expression is associated with the
development of lung adenocarcinoma and emphysema. Lung Cancer.
74:12–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zheng H, Ying H, Wiedemeyer R, Yan H,
Quayle SN, Ivanova EV, Paik JH, Zhang H, Xiao Y, Perry SR, et al:
PLAGL2 regulates Wnt signaling to impede differentiation in neural
stem cells and gliomas. Cancer Cell. 17:497–509. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sekiya R, Maeda M, Yuan H, Asano E, Hyodo
T, Hasegawa H, Ito S, Shibata K, Hamaguchi M, Kikkawa F, et al:
PLAGL2 regulates actin cytoskeletal architecture and cell
migration. Carcinogenesis. 35:1993–2001. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gadea G, de Toledo M, Anguille C and Roux
P: Loss of p53 promotes RhoA-ROCK-dependent cell migration and
invasion in 3D matrices. J Cell Biol. 178:23–30. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu B, Lu C, Song YX, Gao P, Sun JX, Chen
XW, Wang MX, Dong YL, Xu HM and Wang ZN: The role of pleomorphic
adenoma gene-like 2 in gastrointestinal cancer development,
progression, and prognosis. Int J Clin Exp Pathol. 7:3089–3100.
2014.PubMed/NCBI
|
|
41
|
Kas K, Voz ML, Röijer E, Aström AK, Meyen
E, Stenman G and Van de Ven WJ: Promoter swapping between the genes
for a novel zinc finger protein and beta-catenin in pleiomorphic
adenomas with t(3;8)(p21;q12) translocations. Nat Genet.
15:170–174. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Van Dyck F, Delvaux EL, Van de Ven WJ and
Chavez MV: Repression of the transactivating capacity of the
oncoprotein PLAG1 by SUMOylation. J Biol Chem. 279:36121–36131.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lanzara C, Ficarella R, Totaro A, Chen X,
Roberto R, Perrotta S, Lasalandra C, Gasparini P, Iolascon A and
Carella M: Congenital dyserythropoietic anemia type II: Exclusion
of seven candidate genes. Blood Cells Mol Dis. 30:22–29. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Warrier S, Bhuvanalakshmi G, Arfuso F,
Rajan G, Millward M and Dharmarajan A: Cancer stem-like cells from
head and neck cancers are chemosensitized by the Wnt antagonist,
sFRP4, by inducing apoptosis, decreasing stemness, drug resistance
and epithelial to mesenchymal transition. Cancer Gene Ther.
21:381–388. 2014. View Article : Google Scholar : PubMed/NCBI
|
